ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is anticipated to announce its Q4 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $7.89 million for the quarter.
ImmunoPrecise Antibodies Price Performance
ImmunoPrecise Antibodies stock traded down $0.19 during midday trading on Friday, reaching $2.12. The company had a trading volume of 1,586,857 shares, compared to its average volume of 4,451,042. The company has a market capitalization of $97.01 million, a P/E ratio of -1.83 and a beta of 0.44. ImmunoPrecise Antibodies has a 12-month low of $0.27 and a 12-month high of $2.41. The firm's fifty day simple moving average is $1.06 and its 200-day simple moving average is $0.66. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.32 and a quick ratio of 2.11.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on IPA. Benchmark reissued a "speculative buy" rating and issued a $3.00 target price on shares of ImmunoPrecise Antibodies in a research note on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of ImmunoPrecise Antibodies in a research note on Friday, April 11th. Finally, Wall Street Zen raised shares of ImmunoPrecise Antibodies to a "sell" rating in a research note on Saturday, May 24th.
Read Our Latest Stock Report on IPA
About ImmunoPrecise Antibodies
(
Get Free Report)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Recommended Stories
Before you consider ImmunoPrecise Antibodies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.
While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access